AQST Aquestive Therapeutics Inc

Price (delayed)

$2.26

Market cap

$126.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.66

Enterprise value

$213.21M

Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, ...

Highlights
The EPS has surged by 62% year-on-year and by 41% since the previous quarter
AQST's net income has surged by 52% year-on-year and by 39% since the previous quarter
Aquestive Therapeutics's quick ratio has decreased by 41% YoY but it has increased by 4.9% QoQ
AQST's equity is down by 17% year-on-year but it is up by 8% since the previous quarter
The company's gross profit fell by 25% YoY and by 6% QoQ
Aquestive Therapeutics's gross margin has decreased by 16% YoY and by 3.5% QoQ

Key stats

What are the main financial stats of AQST
Market
Shares outstanding
55.92M
Market cap
$126.38M
Enterprise value
$213.21M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.58
Earnings
Revenue
$46.54M
EBIT
-$22.67M
EBITDA
-$20.69M
Free cash flow
$11.09M
Per share
EPS
-$0.66
Free cash flow per share
$0.2
Book value per share
-$1.96
Revenue per share
$0.84
TBVPS
$1.08
Balance sheet
Total assets
$61.29M
Total liabilities
$170.52M
Debt
$113.71M
Equity
-$109.24M
Working capital
$3.32M
Liquidity
Debt to equity
-1.04
Current ratio
1.08
Quick ratio
0.85
Net debt/EBITDA
-4.2
Margins
EBITDA margin
-44.4%
Gross margin
57.2%
Net margin
-71.2%
Operating margin
-79.4%
Efficiency
Return on assets
-58.5%
Return on equity
N/A
Return on invested capital
-19.6%
Return on capital employed
-108.5%
Return on sales
-48.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AQST stock price

How has the Aquestive Therapeutics stock price performed over time
Intraday
-2.16%
1 week
0.89%
1 month
62.59%
1 year
137.89%
YTD
150.53%
QTD
98.25%

Financial performance

How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$46.54M
Gross profit
$26.64M
Operating income
-$36.93M
Net income
-$33.12M
Gross margin
57.2%
Net margin
-71.2%
AQST's net income has surged by 52% year-on-year and by 39% since the previous quarter
The net margin has grown by 46% YoY and by 38% from the previous quarter
The company's gross profit fell by 25% YoY and by 6% QoQ
Aquestive Therapeutics's gross margin has decreased by 16% YoY and by 3.5% QoQ

Growth

What is Aquestive Therapeutics's growth rate over time

Valuation

What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.58
The EPS has surged by 62% year-on-year and by 41% since the previous quarter
AQST's equity is down by 17% year-on-year but it is up by 8% since the previous quarter
AQST's P/S is 170% above its last 4 quarters average of 1.0 and 3.8% above its 5-year quarterly average of 2.6
Aquestive Therapeutics's revenue has decreased by 10% YoY and by 2.4% from the previous quarter

Efficiency

How efficient is Aquestive Therapeutics business performance
The company's return on invested capital has surged by 52% YoY and by 43% QoQ
The return on sales has grown by 49% year-on-year and by 45% since the previous quarter
AQST's ROA is up by 47% year-on-year and by 40% since the previous quarter

Dividends

What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AQST.

Financial health

How did Aquestive Therapeutics financials performed over time
The company's total assets is 64% lower than its total liabilities
Aquestive Therapeutics's quick ratio has decreased by 41% YoY but it has increased by 4.9% QoQ
The current ratio has declined by 39% year-on-year but it has increased by 7% since the previous quarter
AQST's debt to equity is up by 19% year-on-year
AQST's equity is down by 17% year-on-year but it is up by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.